CRBP
Corbus Pharmaceuticals Holdings, Inc.
There isn't enough reported data to score CRBP yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CRBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRBP PE Valuation
CRBP has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRBP Forward outlook
There aren't enough analyst estimates for CRBP to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CRBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.02 | -$0.49 |
| Q2 2026 | -$6.11 | -$1.33 |
| Q1 2026 | -$5.74 | -$1.50 |
| Q4 2025 | -$5.90 | -$2.22 |
| Q3 2025 | -$5.53 | -$0.90 |
| Q2 2025 | -$4.78 | +$0.97 |
| Q1 2025 | -$4.24 | +$2.66 |
| Q4 2024 | -$3.68 | +$6.63 |
CRBP is still losing money, but far less than before: $6.02 per share over the past year, against $53.40 at its worst in late 2020.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over CRBP on earnings, with more consistent year-over-year improvement.
CRBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $97.3K | -92% |
| Q2 2021 | $136.6K | -52% |
| Q1 2021 | $647.8K | -63% |
| Q4 2020 | $658.2K | -74% |
HIMS has the stronger quarterly revenue trend. Revenue is down 100% for CRBP versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2021 | -14257% | -11496 points |
| Q2 2021 | -12230% | +1089 points |
| Q1 2021 | -2379% | -683 points |
| Q4 2020 | -3162% | -2105 points |
| Q3 2020 | -2761% | N/A |
| Q2 2020 | -13319% | N/A |
| Q1 2020 | -1696% | N/A |
| Q4 2019 | -1057% | N/A |
CRBP's operating margin was −14257% last quarter, down 11496 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CRBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.3M | -$5.7M |
| Q2 2026 | -$29.6M | -$13M |
| Q1 2026 | -$25.6M | -$9.2M |
| Q3 2025 | -$15.6M | -$1.6M |
| Q2 2025 | -$16.6M | -$7.7M |
| Q1 2025 | -$16.4M | -$8.5M |
| Q4 2024 | -$10.9M | -$4.9M |
| Q3 2024 | -$13.9M | -$6.8M |
CRBP has the stronger cash trend. Its trailing FCF is down 64% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
CRBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +1.4M shares |
| 1 year | +70% | +8.6M shares |
| 3 years | +398% | +16.7M shares |
| 5 years | +437% | +17M shares |
| Available history | +878% | +18.7M shares |
CRBP has 21M diluted shares, up 70% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRBP Net Leverage
CRBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 4.8 | Oversold |
CRBP's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRBP PE vs Healthcare Sector
CRBP has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 28% below |
| 20 week MA | $7.61 | 55% below |
| 50 week MA | $8.42 | 60% below |
| 100 week MA | $9.05 | 62% below |
| 200 week MA | $14.9 | 77% below |
CRBP is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.3 | $41.7 | -74% |
| 2021 | $41.7 | $21.0 | -50% |
| 2022 | $21.0 | $3.57 | -83% |
| 2023 | $3.57 | $6.04 | +69% |
| 2024 | $6.04 | $12.8 | +111% |
| 2025 | $12.8 | $8.33 | -35% |
| 2026 YTD | $8.33 | $3.41 | -59% |
CRBP's yearly returns have swung widely, from +111% in 2024 to −83% in 2022. It's down 59% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CRBP on returns for 2026, with the stronger performance.